Fortrea (FTRE) to Release Earnings on Monday

Fortrea (NASDAQ:FTRE - Get Free Report) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $609.63 million for the quarter. Fortrea has set its FY 2025 guidance at EPS.

Fortrea (NASDAQ:FTRE - Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The company reported $0.18 earnings per share for the quarter, missing analysts' consensus estimates of $0.36 by ($0.18). The firm had revenue of $697.00 million during the quarter, compared to analyst estimates of $703.22 million. Fortrea had a positive return on equity of 2.00% and a negative net margin of 10.99%. During the same quarter in the previous year, the firm posted $0.19 earnings per share. On average, analysts expect Fortrea to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Fortrea Stock Performance

NASDAQ FTRE traded up $0.12 during midday trading on Wednesday, hitting $5.63. The company had a trading volume of 1,933,522 shares, compared to its average volume of 1,675,649. The firm has a fifty day simple moving average of $7.41 and a two-hundred day simple moving average of $14.54. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.74. The stock has a market cap of $509.74 million, a price-to-earnings ratio of -1.65, a P/E/G ratio of 1.78 and a beta of 2.15. Fortrea has a fifty-two week low of $4.77 and a fifty-two week high of $36.35.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Mizuho dropped their target price on shares of Fortrea from $12.00 to $10.00 and set a "neutral" rating for the company in a research note on Wednesday, April 9th. Evercore ISI reduced their price objective on shares of Fortrea from $20.00 to $15.00 and set an "in-line" rating on the stock in a research note on Tuesday, March 4th. William Blair reaffirmed a "market perform" rating on shares of Fortrea in a research report on Tuesday, March 4th. Truist Financial initiated coverage on Fortrea in a research note on Friday, May 2nd. They issued a "hold" rating and a $7.00 price target on the stock. Finally, The Goldman Sachs Group reduced their target price on shares of Fortrea from $22.00 to $11.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Two investment analysts have rated the stock with a sell rating and eleven have assigned a hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $15.82.

Fortrea Company Profile

Fortrea Holdings Inc, a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum.